Professor Peter Schmid, FRCP, MD, PhD - TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/ZDH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibody–drug conjugates (ADCs) represent a much-needed addition of highly effective agents with unique mechanisms of action to the breast cancer treatment arsenal. TROP2-targeted ADC therapy already has an established role in triple-negative breast cancer (TNBC), and it has recently also demonstrated activity in HR+/HER2- breast cancer. Further investigations are underway in earlier disease settings and in various rational combinations. How can you make the most of these new ADC options in the context of other available therapies, and what is the best way to integrate them into practice? This activity, based on a PeerView Live MasterClass & Practicum educational symposium, addresses these and many other critical questions. By combining insightful analyses of the most recent data with compelling discussions of cases and practicalities, our international expert panel helps you better navigate the complex clinical decisions about when and how to use TROP2-targeting ADCs and the other latest therapies in real-world settings of breast cancer. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanism of action, evolving clinical role, and latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Integrate personalized treatment plans for patients with breast cancer that takes into consideration the latest evidence and guidelines on TROP2-targeting therapies and relevant treatment-, disease-, and patient-specific factors; and Apply a patient-centered approach to care that incorporates shared decision-making, patient education, and engagement that leverages effective multidisciplinary collaboration and care coordination